Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SYNTARA LIMITED Capital/Financing Update 2007

Jul 18, 2007

65830_rns_2007-07-18_b6c46e80-9c38-4867-a804-518ac24f2e24.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003.

Name of entity

Pharmaxis Ltd

ABN

75 082 811 630

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued

Pharmaxis Ltd ordinary shares

  • 2 Number of +securities issued or to be issued (if known) or maximum number which may be issued 79,500
  • 3 Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

Issue of fully paid ordinary shares upon exercise of options granted under the Pharmaxis Ltd Employee Option Plan.

+ See chapter 19 for defined terms.

4 Do the +securities rank equally in allrespects from the date of allotmentwith an existing +class of quoted+securities? Yes
If the additional securities do notrank equally, please state:•the date from which they do•theextenttowhichtheyparticipate for the next dividend,(inthecaseofatrust,distribution) or interest payment•the extent to which they do notrankequally,otherthaninrelation to the next dividend,distribution or interest payment
5 Issue price or consideration 72,000 shares: $0.31255,000 shares: $1.79002,500 shares: $1.9170
6 Purpose of the issue(If issued as consideration for theacquisition of assets, clearly identifythose assets) ExerciseofoptionsEmployee Option Plan underPharmaxisLtd
7 Dates of entering +securities intouncertificated holdings or despatchof certificates 20 July 2007
Number +Class
8 +classNumberandofall+securitiesquotedonASX(including the securities in clause2 if applicable) 178,028,717 Ordinaryfullypaidshares

+ See chapter 19 for defined terms.

Number +Class
9 +classNumberandofall 1,220,000 Optionsexpiringon
+securities not quoted on ASX various dates with an
(including the securities in clause exercisepriceof
2 if applicable) $0.125(ASXCode
PXSAM)
4,746,000 Optionsexpiringon
various dates with an
exercisepriceof
$0.3125 (ASX Code
PXSAO)
500,000 Optionsexpiring30
November 2013 with
an exercise price of
$0.376(ASXCode
22,500 PXSAQ)Optionsexpiring24
March 2014 with an
exercisepriceof
$0.508(ASXCode
PXSAS)
15,000 Optionsexpiring3
June2014withan
exercisepriceof
$0.426(ASXCode
PXSAU)
240,000 Optionsexpiring1
February 2015 with an
exercisepriceof
$0.8340 (ASX Code
PXSAY)
320,000 Optionsexpiring11
May2015withan
exercisepriceof
$1.147(ASXCode
PXSAW)
795,000 Optionsexpiring4August 2015 with an
exercise price of $1.79
(ASX Code PXSAZ)
70,000 Optionsexpiring17
October 2015 with an
exercisepriceof
$2.772(ASXCode
PXSAA)

+ See chapter 19 for defined terms.

270,000 Optionsexpiring12February 2016 with anexercisepriceof$2.194(ASXCodePXSAB)
96,500 Optionsexpiring31May2016withanexercisepriceof$2.034(ASXCodePXSAC)
903,707 Optionsexpiring14August 2016 with anexercisepriceof$1.917(ASXCodePXSAD)
47,500 Optionsexpiring19September 2016 withan exercise price of$1.8918 (ASX CodePXSAE)
72,500 Optionsexpiring13December 2016 withan exercise price of$3.0710 (ASX CodePXSAF)
200,000 Optionsexpiring15March 2016 with anexercisepriceof$2.0680 (ASX CodePXSAG)
237,500 Optionsexpiring17June2017withanexercisepriceof$3.3155 (ASX CodePXSA_)

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

n/a

Part 2 - Bonus issue or pro rata issue

11 Issecurityholderapprovalrequired?
12 Is the issue renounceable or non
renounceable?
13 Ratio in which the +securities willbe offered

+ See chapter 19 for defined terms.

  • 14 +Class of +securities to which the offer relates
  • 15 +Record date to determine entitlements
  • 16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?
  • 17 Policy for deciding entitlements in relation to fractions
  • 18 Names of countries in which the entity has +security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with.

Cross reference: rule 7.7.

  • 19 Closing date for receipt of acceptances or renunciations
  • 20 Names of any underwriters
  • 21 Amount of any underwriting fee or commission
  • 22 Names of any brokers to the issue
  • 23 Fee or commission payable to the broker to the issue
  • 24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders
  • 25 If the issue is contingent on +security holders' approval, the date of the meeting
  • 26 Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled

+ See chapter 19 for defined terms.
------------------------------------- --
27 If the entity has issued options, andthe terms entitle option holders toparticipate on exercise, the date onwhich notices will be sent to optionholders
28 Date rights trading will begin (ifapplicable)
29 Date rights trading will end (ifapplicable)
30 How do +security holders sell theirentitlementsinfullthroughabroker?
31 How do +security holders sell partof their entitlements through abroker and accept for the balance?
32 How do +security holders disposeof their entitlements (except by salethrough a broker)?
33 +Despatch date

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

+ See chapter 19 for defined terms.

35 If the +securities are +equity securities, the names of the 20 largest holders of theadditional +securities, and the number and percentage of additional +securities held bythose holders
36 If the +securities are +equity securities, a distribution schedule of the additional+securities setting out the number of holders in the categories1 - 1,0001,001 - 5,0005,001 - 10,00010,001 - 100,000100,001 and over
37 A copy of any trust deed for the additional +securities
Entities that have ticked box 34(b)
38 Number of securities for which+quotation is sought
39 +securitiesClassofforwhichquotation is sought
40 Do the +securities rank equally in allrespects from the date of allotmentwith an existing +class of quoted+securities?
If the additional securities do notrank equally, please state:•the date from which they do•theextenttowhichtheyparticipate for the next dividend,(inthecaseofatrust,distribution) or interest payment•the extent to which they do notrankequally,otherthaninrelation to the next dividend,distribution or interest payment
41 Reason for request for quotationnowExample: In the case of restricted securities, end ofrestriction period
(ifissueduponconversionofanother security, clearly identify thatother security)
Number +Class

+ See chapter 19 for defined terms.

42 Number and +class of all +securities quoted on ASX (including the securities in clause 38)

Quotation agreement

  • 1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.
  • 2 We warrant the following to ASX.
    • The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
    • There is no reason why those +securities should not be granted +quotation.
    • An offer of the + securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

  • Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
  • We warrant that if confirmation is required under section 1017F of the Corporations Act in relation to the +securities to be quoted, it has been provided at the time that we request that the +securities be quoted.
  • If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

+ See chapter 19 for defined terms.

  • 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
  • 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: ............................................................ Date: .. 19th July 2007... (Company secretary)

Print name: ......David McGarvey............

== == == == ==

+ See chapter 19 for defined terms.